[{"address1": "5505 Morehouse Drive", "address2": "Suite 100", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 267 4467", "website": "https://www.artivabio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.", "fullTimeEmployees": 105, "companyOfficers": [{"maxAge": 1, "name": "Dr. Fred  Aslan M.D.", "age": 49, "title": "President, CEO & Director", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 963111, "exercisedValue": 0, "unexercisedValue": 2049802}, {"maxAge": 1, "name": "Ms. Neha  Krishnamohan", "age": 37, "title": "CFO & Executive VP of Corporate Development", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 595515, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer Kinsbruner Bush Esq., J.D.", "age": 49, "title": "Executive VP, COO, Chief Legal Officer, Corporate Secretary & Compliance Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 676166, "exercisedValue": 0, "unexercisedValue": 234059}, {"maxAge": 1, "name": "Dr. Peter  Flynn Ph.D.", "age": 50, "title": "Co-Founder & Strategic Advisor", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 499368, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher P. Horan", "age": 57, "title": "Chief Technical Operations Officer", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 612234, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Heather  Raymon Ph.D.", "age": 59, "title": "Senior Vice President of Research & Early Development", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Moriarty Ph.D.", "title": "Senior VP of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin  Dewees", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Feng  Xu", "title": "Senior Vice President of Biometrics", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Subhashis  Banerjee M.D.", "age": 67, "title": "Chief Medical Officer", "yearBorn": 1957, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 3.94, "open": 4.0, "dayLow": 3.99, "dayHigh": 4.24, "regularMarketPreviousClose": 3.94, "regularMarketOpen": 4.0, "regularMarketDayLow": 3.99, "regularMarketDayHigh": 4.24, "payoutRatio": 0.0, "forwardPE": -1.2086957, "volume": 184728, "regularMarketVolume": 184728, "averageVolume": 2103731, "averageVolume10days": 809590, "averageDailyVolume10Day": 809590, "bid": 3.91, "ask": 4.11, "bidSize": 7, "askSize": 7, "marketCap": 101855432, "fiftyTwoWeekLow": 1.47, "fiftyTwoWeekHigh": 15.49, "allTimeHigh": 17.31, "allTimeLow": 1.47, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 3.2842, "twoHundredDayAverage": 3.14665, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -27285572, "profitMargins": 0.0, "floatShares": 5407131, "sharesOutstanding": 24425762, "sharesShort": 203790, "sharesShortPriorMonth": 290934, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.0083, "heldPercentInsiders": 0.19875, "heldPercentInstitutions": 0.75921, "shortRatio": 2.42, "shortPercentOfFloat": 0.0208, "impliedSharesOutstanding": 26218923, "bookValue": 6.11, "priceToBook": 0.6824877, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -75132000, "trailingEps": -6.15, "forwardEps": -3.45, "enterpriseToEbitda": 0.345, "52WeekChange": -0.6273458, "SandP52WeekChange": 0.19736934, "quoteType": "EQUITY", "currentPrice": 4.17, "targetHighPrice": 23.0, "targetLowPrice": 10.0, "targetMeanPrice": 16.4, "targetMedianPrice": 18.0, "recommendationKey": "none", "numberOfAnalystOpinions": 5, "totalCash": 142364992, "totalCashPerShare": 5.828, "ebitda": -79073000, "totalDebt": 13224000, "quickRatio": 13.317, "currentRatio": 13.843, "totalRevenue": 0, "debtToEquity": 8.873, "revenuePerShare": 0.0, "returnOnAssets": -0.41573003, "returnOnEquity": -0.86182, "grossProfits": 0, "freeCashflow": -45932376, "operatingCashflow": -69085000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ARTV", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Artiva Biotherapeutics, Inc.", "longName": "Artiva Biotherapeutics, Inc.", "fiftyDayAverageChange": 0.8858001, "fiftyDayAverageChangePercent": 0.26971564, "twoHundredDayAverageChange": 1.02335, "twoHundredDayAverageChangePercent": 0.3252189, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2024-07-19", "cryptoTradeable": false, "regularMarketChangePercent": 5.83756, "regularMarketPrice": 4.17, "corporateActions": [], "postMarketTime": 1761955006, "regularMarketTime": 1761940802, "exchange": "NGM", "messageBoardId": "finmb_672643147", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "epsTrailingTwelveMonths": -6.15, "epsForward": -3.45, "epsCurrentYear": -3.13, "priceEpsCurrentYear": -1.3322684, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1721395800000, "postMarketChangePercent": -3.5971246, "postMarketPrice": 4.02, "postMarketChange": -0.1500001, "regularMarketChange": 0.23, "regularMarketDayRange": "3.99 - 4.24", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 2103731, "fiftyTwoWeekLowChange": 2.7, "fiftyTwoWeekLowChangePercent": 1.8367347, "fiftyTwoWeekRange": "1.47 - 15.49", "fiftyTwoWeekHighChange": -11.32, "fiftyTwoWeekHighChangePercent": -0.7307941, "fiftyTwoWeekChangePercent": -62.73458, "earningsTimestampStart": 1754569800, "earningsTimestampEnd": 1754569800, "isEarningsDateEstimate": true, "displayName": "Artiva Biotherapeutics", "trailingPegRatio": null, "__fetch_time": "2025-11-01"}]